Bio
Dr. Jeyun Jo received his Pharm.D. from Pusan National University in 2016 and his Ph.D. in pharmacy at the same institution in 2021. His thesis studies focused on the first total synthesis of anmindenol A and optimization of 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cells. He then worked for one year as a senior research scientist at Chong Kun Dang, a leading pharmaceutical company in Korea, where he developed large-sacale synthetic processes for engineered peptides. In May 2022, he joined the Bogyo lab at Stanford University as a postdoctoral fellow. His current research focuses on developing highly selective inhibitors and activity-based probes targeting specific serine hydrolases in pathogenic bacteria and cancer.
